Equibles does not estimate personal net worth.
Get an email with a short summary when Amylyx Pharmaceuticals, Inc. publishes a filing, an earnings call transcript or a press release.
Get AMLX alertsJames Frates is recorded as CFO at Amylyx Pharmaceuticals, Inc. (AMLX). The newest filing on record that lists James Frates as CFO at Amylyx Pharmaceuticals, Inc. (AMLX) is dated April 23, 2026. Earlier roles on record: CFO at Alkermes plc. (ALKS) until January 11, 2021. The proxy statement of Amylyx Pharmaceuticals, Inc. reports total compensation of $1,375,327 for James Frates in fiscal 2025, including a base salary of $540,600. Disclosed compensation is on record for 5 fiscal years. James Frates has spoken on 13 earnings calls across 2 companies, most recently for Amylyx Pharmaceuticals, Inc. on November 5, 2026. Those appearances were for Amylyx Pharmaceuticals, Inc. (AMLX) and Alkermes plc. (ALKS). Amylyx Pharmaceuticals, Inc. is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Other companies whose calls James Frates spoke on are classified in the Healthcare sector. Other leadership on record at Amylyx Pharmaceuticals, Inc. includes Joshua Cohen (CEO and Board Member), Justin Klee (CEO and Board Member), Gina M. Mazzariello (General Counsel) and 2 others.
“We had an excellent quarter from a financial point of view. The success of the lucidity trial has allowed us to move to the next phase of growth, executing on our NDA preparation, scaling our commercial organization, and building long-term supply by investing in both our current and a new supplier.”
“Our financial results for the first quarter were in line with our plans and reflect our focus on the Phase III LUCIDITY trial and targeted investments in advancing our broader pipeline.”
“Our financial position is strong as we focus on careful execution of LUCIDITY and preparing the company for a launch in 2027, should avexitide be approved by the FDA.”
“We ended the second quarter with a cash position of $180.8 million compared to $204.1 million at the end of the first quarter.”
“We ended 2024 in a solid cash position of $176.5 million, which does not include the approximately $65.5 million in net proceeds from our public offering, which closed on January 13, 2025.”
Start not stated–present
Last confirmed April 23, 2026
Start not stated–2021-01-11
Drug Manufacturers - Specialty & Generic · Healthcare
CFO
ALKS
Drug Manufacturers - Specialty & Generic · Healthcare
CFO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Amylyx Pharmaceuticals, Inc. (AMLX) | Chief Financial Officer | $540,600 | $1,375,327 |
| 2024 | Amylyx Pharmaceuticals, Inc. (AMLX) | Chief Financial Officer | $540,600 | $2,540,353 |
| 2023 | Amylyx Pharmaceuticals, Inc. (AMLX) | Chief Financial Officer | $510,000 | $3,510,377 |
| 2022 | Amylyx Pharmaceuticals, Inc. (AMLX) | Chief Financial Officer | $439,500 | $3,658,945 |
| 2021 | Amylyx Pharmaceuticals, Inc. (AMLX) | Chief Financial Officer | $375,000 | $3,255,900 |
